News Sentiment

DCTH sentiment intelligence

Delcath Systems Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 13.01 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-1.4% over one week, +11.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Understanding Momentum Shifts in (DCTH)

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -1.4% Price digesting
Trend fit Trend active 11.0% over four weeks
Fair value 43.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 37
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
TradingView 8
TradingKey 7
Stock Titan 5
Stock Traders Daily 3
GuruFocus 2
marketscreener.com 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 24
Analyst action 4
Regulatory and legal 3
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
TradingKey Direct company coverage

Delcath Systems Inc (DCTH) Earnings Forecast: Future EPS & Revenue Growth Estimates

Delcath Systems Inc (DCTH) has an earnings forecast score of 8.57, ranking 26th in the Healthcare Equipment & Supplies industry, with an average price target of $22.00. Based on 6 analysts, the stock has a "Buy" rating with a target price of $22.333, representing an upside of 89.

Tone
Positive 77/100
Event
Earnings
Published
17 Jun 2026 17:40
Source
TradingKey
GuruFocus Direct company coverage

Q1 2026 Delcath Systems Inc Earnings Call Transcript

This document contains the transcript for Delcath Systems Inc.'s Q1 2026 earnings conference call, which took place on May 7, 2026, at 12:30 PM GMT. The call commenced with an introduction and then transitioned to discussions of the company's first-quarter 2026 earnings. The prov

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 07:40
Source
GuruFocus
MLQ.ai Direct company coverage

Delcath Systems, Inc. Analyst Forecast (DCTH) — MLQ

This article provides an analyst forecast for Delcath Systems, Inc. (DCTH), showing a "Buy" consensus from 11 analysts with a 12-month average target price of $23.00. It details forward estimates for revenue, EPS, and net income through 2030, alongside recent grade changes and pr

Tone
Positive 71/100
Event
Earnings
Published
08 Jun 2026 11:09
Source
MLQ.ai
TradingView Direct company coverage

Delcath Systems, Inc. Stock 12‑Month Price Target Cut to $20.83, Implies 95% Upside

Delcath Systems, Inc.'s average 12-month price target has been lowered to $20.83 from $21.71 by 6 analysts, with individual forecasts ranging from $16 to $30. This new target suggests a potential upside of approximately 95% based on the June 5 closing price. The consensus analyst

Tone
Positive 72/100
Event
Analyst action
Published
06 Jun 2026 16:38
Source
TradingView
Stock Titan Direct company coverage

European cancer guidelines add Delcath liver therapy for eye melanoma

Delcath Systems' CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included in the European Society for Medical Oncology (ESMO)–EURACAN Clinical Practice Guidelines for uveal melanoma. This inclusion validates M-PHP as a recommended li

Tone
Positive 71/100
Event
Market update
Published
06 Jun 2026 00:38
Source
Stock Titan
Quantisnow Direct company coverage

FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

The article announces that DELCATH SYSTEMS INC (DCTH) has received FDA approval for its product, HEPZATO. This information was disseminated by Quantisnow, a platform providing real-time market data and news to investors. Quantisnow Plus members were alerted of this development sh

Tone
Positive 92/100
Event
Regulatory and legal
Published
29 May 2026 11:09
Source
Quantisnow
Stock Traders Daily Direct company coverage

(DCTH) Movement Within Algorithmic Entry Frameworks

Delcath Systems Inc. (NASDAQ: DCTH) is exhibiting weak near-term sentiment that may lead to a resumption of long-term weakness. The article highlights an exceptional 57.7:1 risk-reward short setup and outlines three distinct AI-generated trading strategies with specific entry zon

Tone
Negative 30/100
Event
Market update
Published
28 May 2026 17:46
Source
Stock Traders Daily
Market source Direct company coverage

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. announced the publication of two investigator-initiated trials-in-progress abstracts for the 2026 ASCO Annual Meeting. These abstracts detail ongoing clinical investigations using Delcath's HEPZATO KIT™ for metastatic melanoma involving the liver. The trials

Tone
Positive 70/100
Event
Regulatory and legal
Published
27 May 2026 09:10
Source
Market source
Stock Titan Direct company coverage

Liver melanoma trials test HEPZATO with systemic treatments at ASCO 2026

Delcath Systems announced the publication of two investigator-initiated trials-in-progress abstracts for presentation at the 2026 ASCO Annual Meeting. These abstracts detail ongoing clinical investigations evaluating HEPZATO KIT™ Hepatic Delivery System (HDS) with melphalan in co

Tone
Positive 75/100
Event
Regulatory and legal
Published
27 May 2026 08:10
Source
Stock Titan